CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer
Science Advances · 2026
DOI: 10.1126/sciadv.aef1693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Qing Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Institute of Clinical Research, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai…. Hauptthemen laut MEDLINE: CREB-Binding Protein, Lung Neoplasms, Epigenesis, Genetic, Small Cell Lung Carcinoma. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Shanghai Pujiang Scholar Program.
Abstract (Originalsprache)
Most small cell lung cancers (SCLCs) exhibit low immunogenicity and intrinsic resistance to immunotherapy, yet the underlying mechanisms remain poorly understood. Here, we identify CREBBP loss, a frequent genetic alteration in SCLC, as a key suppressor of tumor cell-intrinsic immune responses that drives an immune-cold tumor microenvironment in Rb1/Trp53 -driven autochthonous mouse models. Consistently, Crebbp deletion promotes immune escape in syngeneic SCLC models. Mechanistically, Crebbp loss suppresses Sting and major histocompatibility complex class-I expression by reducing histone H3 acetylation. Notably, HDAC inhibition restores histone acetylation, reactivates these silenced genes, and induces tumor cell-intrinsic immune responses. Moreover, pharmacological HDAC inhibition synergizes with immune checkpoint blockade to suppress tumor growth in both Crebbp -mutant and Crebbp -wild-type SCLCs, with a more prominent effect in Crebbp -mutant tumors. Collectively, these findings establish CREBBP loss as a key mechanism of immune evasion and immunotherapy resistance in SCLC, highlighting HDAC inhibition as a promising strategy to enhance immunotherapy efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Institute of Clinical Research, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Pathology, Yale School of Medicine, Yale University, New Haven, CT, USA.
- Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
- Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
ORCID-Profile: Qing Gao, Chaoliang Xu, Yan Zhang, David MacPherson, Deshui Jia
Förderung
- National Natural Science Foundation of China
- Shanghai Pujiang Scholar Program
Zitieren
APA
Gao, Q., Wei, K., Pan, D., Xu, C., Xi, Y., Zhang, Y., Augert, A., MacPherson, D., & Jia, D. (2026). CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer. Science Advances. https://doi.org/10.1126/sciadv.aef1693
Vancouver
Gao Q, Wei K, Pan D, Xu C, Xi Y, Zhang Y, et al. CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer. Science Advances. 2026. doi:10.1126/sciadv.aef1693
BibTeX
@article{Gao2026,
author = {Gao, Qing and Wei, Kehong and Pan, Deshen and Xu, Chaoliang and Xi, Yufei and Zhang, Yan and Augert, Arnaud and MacPherson, David and Jia, Deshui},
title = {CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aef1693}
}
EUVIMED